Skip to content

The safety and effectiveness of anticoagulation strategies of Nafamostat Mesilate for hemodialysis in patients at high risk of blood clotting:a single-center randomized trial.

The safety and effectiveness of anticoagulation strategies of Nafamostat Mesilate for hemodialysis in patients at high risk of blood clotting:a single-center randomized trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300071613
Enrollment
Unknown
Registered
2023-05-19
Start date
2023-06-01
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Maintenance hemodialysis patients

Interventions

Nafamostat Mesilate:Flush the circuit with 1000ml of normal saline. Dissolve 20mg of Nafamostat Mesilate in at least 2 ml of 5% glucose and add it to 500ml of normal saline to pre-fill the circuit and
Non-anticoagulant group:Flush the circuit with 1000ml of normal saline prior to use. During dialysis, clamp the arterial end of the extracorporeal circuit every 60 minutes and flush the circuit and fi

Sponsors

Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1)Patients with end-stage renal disease and receiving maintenance hemodialysis; 2)Aged 18 years or older; 3)Undergoing hemodialysis 2-3 times per week, with each session lasting 4 hours; 4)Treatment modality is hemodialysis with a dialysate flow rate of up to 500ml/min and a blood flow rate of 3.5-4ml/min.kg; 5)Presence of significant bleeding or high risk of bleeding (defined as within 3 days after active bleeding, within 3 days after invasive procedures or surgeries, or within 7 days before scheduled surgeries or invasive procedures); 6)Signed informed consent.

Exclusion criteria

Exclusion criteria: 1)Patients with hematological diseases (such as hemophilia, allergic purpura, etc.); 2)Patients who have used anticoagulants, antiplatelet drugs or other drugs affecting coagulation function within the past week; 3)Patients with pulmonary bleeding diseases, those scheduled for bronchoscopy, or those who have undergone bronchoscopy; 4)Patients with a pre-dialysis potassium level higher than 6.5mmol/L; 5)Patients with severe allergies.

Design outcomes

Primary

MeasureTime frame
Extracorporeal circuit occlusion event;

Secondary

MeasureTime frame
Acute complication;

Countries

China

Contacts

Public ContactFeng Zhonglin

Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University

13828431229@138.com+86 138 2843 1229

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026